Productaducanumab
Aducanumab
A monoclonal antibody drug targeting beta-amyloid for the treatment of Alzheimer's disease that can clear amyloid plaques in the brain.
Timeline (last 90 days)
Oct 24
Anti-amyloid monoclonal antibodies are a class of intravenously administered antibody drugs that can specifically bind beta-amyloid in the brain and promote its clearance; representative drugs include aducanumab and lecanemab.
Unverified50%